S&P 500   2,607.05 (+2.58%)
DOW   22,113.93 (+2.21%)
QQQ   191.23 (+3.20%)
AAPL   252.84 (+2.06%)
FB   163.87 (+4.52%)
MSFT   159.56 (+6.59%)
GOOGL   1,137.88 (+2.49%)
AMZN   1,956.42 (+2.96%)
CGC   14.70 (+0.75%)
NVDA   264.44 (+4.63%)
BABA   190.69 (+1.11%)
MU   45.06 (+3.63%)
GE   7.88 (+3.41%)
TSLA   506.78 (-1.47%)
AMD   48.12 (+3.31%)
T   30.07 (+0.77%)
ACB   0.93 (-9.71%)
F   5.04 (-3.08%)
NFLX   371.66 (+4.07%)
BAC   22.19 (+2.73%)
GILD   75.58 (+3.75%)
DIS   97.19 (+0.81%)
S&P 500   2,607.05 (+2.58%)
DOW   22,113.93 (+2.21%)
QQQ   191.23 (+3.20%)
AAPL   252.84 (+2.06%)
FB   163.87 (+4.52%)
MSFT   159.56 (+6.59%)
GOOGL   1,137.88 (+2.49%)
AMZN   1,956.42 (+2.96%)
CGC   14.70 (+0.75%)
NVDA   264.44 (+4.63%)
BABA   190.69 (+1.11%)
MU   45.06 (+3.63%)
GE   7.88 (+3.41%)
TSLA   506.78 (-1.47%)
AMD   48.12 (+3.31%)
T   30.07 (+0.77%)
ACB   0.93 (-9.71%)
F   5.04 (-3.08%)
NFLX   371.66 (+4.07%)
BAC   22.19 (+2.73%)
GILD   75.58 (+3.75%)
DIS   97.19 (+0.81%)
S&P 500   2,607.05 (+2.58%)
DOW   22,113.93 (+2.21%)
QQQ   191.23 (+3.20%)
AAPL   252.84 (+2.06%)
FB   163.87 (+4.52%)
MSFT   159.56 (+6.59%)
GOOGL   1,137.88 (+2.49%)
AMZN   1,956.42 (+2.96%)
CGC   14.70 (+0.75%)
NVDA   264.44 (+4.63%)
BABA   190.69 (+1.11%)
MU   45.06 (+3.63%)
GE   7.88 (+3.41%)
TSLA   506.78 (-1.47%)
AMD   48.12 (+3.31%)
T   30.07 (+0.77%)
ACB   0.93 (-9.71%)
F   5.04 (-3.08%)
NFLX   371.66 (+4.07%)
BAC   22.19 (+2.73%)
GILD   75.58 (+3.75%)
DIS   97.19 (+0.81%)
S&P 500   2,607.05 (+2.58%)
DOW   22,113.93 (+2.21%)
QQQ   191.23 (+3.20%)
AAPL   252.84 (+2.06%)
FB   163.87 (+4.52%)
MSFT   159.56 (+6.59%)
GOOGL   1,137.88 (+2.49%)
AMZN   1,956.42 (+2.96%)
CGC   14.70 (+0.75%)
NVDA   264.44 (+4.63%)
BABA   190.69 (+1.11%)
MU   45.06 (+3.63%)
GE   7.88 (+3.41%)
TSLA   506.78 (-1.47%)
AMD   48.12 (+3.31%)
T   30.07 (+0.77%)
ACB   0.93 (-9.71%)
F   5.04 (-3.08%)
NFLX   371.66 (+4.07%)
BAC   22.19 (+2.73%)
GILD   75.58 (+3.75%)
DIS   97.19 (+0.81%)
Log in

NASDAQ:ICPT - Intercept Pharmaceuticals Stock Price, Forecast & News

$65.69
+0.62 (+0.95 %)
(As of 03/30/2020 01:29 PM ET)
Today's Range
$62.88
Now: $65.69
$66.90
50-Day Range
$48.34
MA: $82.90
$98.33
52-Week Range
$47.57
Now: $65.69
$125.00
Volume149,269 shs
Average Volume717,174 shs
Market Capitalization$2.16 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.53
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development. Intercept Pharmaceuticals, Inc. has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China. The company was founded in 2002 and is headquartered in New York, New York.
Read More
Intercept Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ICPT
CUSIP45845P10
Phone646-747-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$252 million
Book Value$1.57 per share

Profitability

Net Income$-344,680,000.00
Net Margins-136.78%

Miscellaneous

Employees483
Market Cap$2.16 billion
Next Earnings Date5/13/2020 (Estimated)
OptionableOptionable

Receive ICPT News and Ratings via Email

Sign-up to receive the latest news and ratings for ICPT and its competitors with MarketBeat's FREE daily newsletter.


Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions

How has Intercept Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Intercept Pharmaceuticals' stock was trading at $77.60 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ICPT shares have decreased by 15.3% and is now trading at $65.69. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Intercept Pharmaceuticals?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings, 13 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Intercept Pharmaceuticals.

When is Intercept Pharmaceuticals' next earnings date?

Intercept Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Intercept Pharmaceuticals.

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) announced its quarterly earnings data on Tuesday, February, 25th. The biopharmaceutical company reported ($2.99) earnings per share for the quarter, missing the Zacks' consensus estimate of ($2.52) by $0.47. The biopharmaceutical company earned $71.50 million during the quarter, compared to analyst estimates of $68.19 million. Intercept Pharmaceuticals had a negative return on equity of 455.79% and a negative net margin of 136.78%. The business's revenue was up 34.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($2.97) EPS. View Intercept Pharmaceuticals' earnings history.

What price target have analysts set for ICPT?

17 brokerages have issued 1-year price objectives for Intercept Pharmaceuticals' stock. Their forecasts range from $102.00 to $257.00. On average, they expect Intercept Pharmaceuticals' stock price to reach $152.20 in the next year. This suggests a possible upside of 131.7% from the stock's current price. View analysts' price targets for Intercept Pharmaceuticals.

What are Wall Street analysts saying about Intercept Pharmaceuticals stock?

Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Intercept’s lead drug Ocaliva’s performance has been strong in the year so far. Management’s efforts to increase awareness about the label update of the drug in 2018 and expand sales force across the United States, thereafter, are yielding results. Solid growth in patient enrollment is likely to drive the company’s performance. Meanwhile, Intercept is working to expand the drug’s label in the promising NASH space. While the failure of Gilead’s late-stage study on selonsertib in patients suffering from compensated cirrhosis due to NASH puts Intercept ahead in the race, additional results from the REGENERATE study in NASH were mixed and did not impress investors. Nevertheless, a potential approval in this indication will significantly boost growth. However, shares have underperformed the industry in the year so far." (10/14/2019)
  • 2. Stifel Nicolaus analysts commented, "We are reiterating our Hold rating on ICPT after the company reported a slight 2Q19 beat on Ocaliva revenues, which appear to have been aided by a benefit in channel inventories. With that said, our thesis remains unchanged and we think there are too many unknown variables in terms of OCA’s potential adcom/approval and launch in NASH for us to be comfortable recommending the stock here. Management remains on track to file its NDA for OCA in NASH by the end of this quarter followed by its MAA filing in the EU in 4Q19. We think investor focus remains on the potential for OCA in NASH and in particular: whether or not ICPT’s filing of a NDA for OCA in NASH (rather than a sNDA) can lead to bi- furcated/indication based pricing, potential payer/reimbursement dynamics in the NASH category and the use of non-invasive biomarkers vs. biopsy for diagnosis." (8/12/2019)

Has Intercept Pharmaceuticals been receiving favorable news coverage?

Media stories about ICPT stock have been trending very positive recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Intercept Pharmaceuticals earned a daily sentiment score of 4.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutIntercept Pharmaceuticals.

Who are some of Intercept Pharmaceuticals' key competitors?

What other stocks do shareholders of Intercept Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), Alibaba Group (BABA), Netflix (NFLX), NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Micron Technology (MU), Celgene (CELG) and Regeneron Pharmaceuticals (REGN).

Who are Intercept Pharmaceuticals' key executives?

Intercept Pharmaceuticals' management team includes the following people:
  • Dr. Mark Pruzanski, Founder, CEO, Pres & Director (Age 51)
  • Mr. Sandip S. Kapadia, CFO, Treasurer & Principal Accounting Officer (Age 49)
  • Mr. Jerome B. Durso, Chief Operating Officer (Age 51)
  • Mr. Ryan T. Sullivan, Gen. Counsel & Sec. (Age 43)
  • Dr. Gail Cawkwell, Sr. VP of Medical Affairs, Safety & Pharmacovigilance (Age 57)

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

Who are Intercept Pharmaceuticals' major shareholders?

Intercept Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include First Trust Advisors LP (2.38%), Macquarie Group Ltd. (1.66%), Macquarie Group Ltd. (1.66%), Geode Capital Management LLC (1.10%), Norges Bank (0.92%) and Pinnacle Associates Ltd. (0.53%). Company insiders that own Intercept Pharmaceuticals stock include Christian Weyer, David A Ford, David Shapiro, Francesco Micheli, Gail Cawkwell, Jason Campagna, Keith Michael Gottesdiener, Lisa Bright, Luca Benatti, Mark Pruzanski, Paolo Fundaro, Ryan T Sullivan, SPA Genextra and Srinivas Akkaraju. View institutional ownership trends for Intercept Pharmaceuticals.

Which major investors are selling Intercept Pharmaceuticals stock?

ICPT stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., First Trust Advisors LP, Peregrine Capital Management LLC, Rafferty Asset Management LLC, Spark Investment Management LLC, Schonfeld Strategic Advisors LLC, Man Group plc, and Chicago Equity Partners LLC. Company insiders that have sold Intercept Pharmaceuticals company stock in the last year include Christian Weyer, David A Ford, David Shapiro, Gail Cawkwell, Jason Campagna, Lisa Bright, Mark Pruzanski, and Ryan T Sullivan. View insider buying and selling activity for Intercept Pharmaceuticals.

Which major investors are buying Intercept Pharmaceuticals stock?

ICPT stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Macquarie Group Ltd., Macquarie Group Ltd., Renaissance Technologies LLC, Pictet Asset Management Ltd., California Public Employees Retirement System, Cubist Systematic Strategies LLC, and Geode Capital Management LLC. Company insiders that have bought Intercept Pharmaceuticals stock in the last two years include Francesco Micheli, Keith Michael Gottesdiener, Luca Benatti, Mark Pruzanski, and Srinivas Akkaraju. View insider buying and selling activity for Intercept Pharmaceuticals.

How do I buy shares of Intercept Pharmaceuticals?

Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Intercept Pharmaceuticals' stock price today?

One share of ICPT stock can currently be purchased for approximately $65.69.

How big of a company is Intercept Pharmaceuticals?

Intercept Pharmaceuticals has a market capitalization of $2.16 billion and generates $252 million in revenue each year. The biopharmaceutical company earns $-344,680,000.00 in net income (profit) each year or ($10.89) on an earnings per share basis. Intercept Pharmaceuticals employs 483 workers across the globe. View additional information about Intercept Pharmaceuticals.

What is Intercept Pharmaceuticals' official website?

The official website for Intercept Pharmaceuticals is http://www.interceptpharma.com/.

How can I contact Intercept Pharmaceuticals?

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]


MarketBeat Community Rating for Intercept Pharmaceuticals (NASDAQ ICPT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  1,001 (Vote Outperform)
Underperform Votes:  613 (Vote Underperform)
Total Votes:  1,614
MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote "Outperform" if you believe ICPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Featured Article: How Short Selling Works

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel